Evidence map›Paper›PMID 33143283›Full record

ReviewCancers2020

Cannabidiol (CBD) as a Promising Anti-Cancer Drug.

Emily S Seltzer, Andrea K Watters, Danny MacKenzie, Lauren M Granat, Dong Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 3 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 3 syntheses or guidelines pooled it, 239 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Cannabidiol-Ion Channel Interactions Represent a Promising Preventive and Therapeutic Strategy in Hepatocellular Carcinoma.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  18. Article
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emily S SeltzerDepartment of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, NY 11568, USA.ORCID 0000-0002-5404-424X
Andrea K WattersDepartment of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, NY 11568, USA.
Danny MacKenzieDepartment of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, NY 11568, USA.ORCID 0000-0002-3632-6040
Lauren M GranatDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA.ORCID 0000-0001-8362-5492
Dong ZhangDepartment of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, NY 11568, USA.ORCID 0000-0002-4515-2070
New York Institute of Technology · USCleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, cannabinoids, such as cannabidiol (CBD) and Δ

Indexed as

anti-cancer drugCannabidiolCannbinoidsCBD

Identifiers

PMID33143283
PMCPMC7693730
OpenAlexW3097411329

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.